We asked Prof. James Spratt and Dr. Simon Wilson to share their IVL journey since the launch of Shockwave C2 five years ago and their initial experience with the new Shockwave C2+. Regardless of the physicians experience, the overall opinion is the same: “IVL is quick to learn, easy to use, very safe, and effective across a broad range of calcium types that other technologies can’t compete with. It has changed the landscape for calcium modification and the new Shockwave C2+ catheter continues to expand physicians ability to deal effectively and safely with severe calcium in a broader range of patients.” Read more below:
Read More
Topics:
Coronary IVL,
IVL Technology,
SWAV News,
Shockwave C2
In the latest ChalkTalk episode, we sat down with Dr. Jonathan Hill, Royal Brompton Hospital, London, to have a discussion about his 5-year journey with Coronary IVL. Being involved in the first Disrupt CAD clinical studies and one of the first commercial users of the technology, he has vast experience, which he has translated into many best practices, including creating the “pulse management strategy” approach to energy distribution in the artery. In our conversation, Dr. Hill speaks to some of the most memorable moments in his interventional career, his insights into the new Shockwave C2+ catheter and his outlook on EuroPCR 2023 and beyond. We hope you enjoy this personal insights and don’t miss our latest blogpost for more information on Shockwave IVL at EuroPCR 2023 https://blog.shockwavemedical.com/europcr-2023
Read More
Topics:
Coronary IVL,
IVL Technology,
Shockwave C2
Attending SCAI next week? Get ready, because Shockwave ain't bringing nothing but heat. Take a look at the hot topics SWAV has in store for you this year including:
Read More
Topics:
Coronary IVL,
IVL Technology,
Shockwave C2,
Coronary Conferences
A partir de 2 de Maio, a Shockwave Medical está diretamente em Portugal.
Read More
Topics:
IVL Technology,
SWAV News
Desde el 2 de mayo, Shockwave Medical cuenta con un Equipo de Venta Directa en España.
Read More
Topics:
IVL Technology,
SWAV News
After 5 years of innovating together, we’re just getting started! Join us at EuroPCR 2023 to celebrate with us 5 years of Coronary IVL and find out more about our brand-new catheter, Shockwave C2+. We will go through the results of the latest clinical studies in our Symposium and discuss the main features of the new Shockwave C2+ in our Case in Point session.
With the recent acquisition of Neovasc and their innovative Reducer™ device, we are creating new opportunities for patients and physicians in the treatment of refractory angina. Join us at the Tools & Techniques session to learn how we are working to bring these patients relief from their symptoms and hopefully improve their quality of life.
À bientôt à Paris!
Read More
Topics:
Coronary IVL,
IVL Technology,
Shockwave C2,
Coronary Conferences
Learn How Coronary IVL is Currently Utilized Within Non-Surgical Facilities
Want to learn more about Coronary IVL’s place within existing facilities lacking surgical cardiac backup? Cardiovascular Business and Shockwave Medical is excited to present this on demand webinar titled: No Surgical Backup? No Problem. This webinar consists of an expert panel who provide real-world insights and implications of Coronary IVL usage within non-surgical facilities. Topics within this event include a review of the recent SCAI Expert Consensus Document regarding PCI within non-surgical facilities, an introduction to Shockwave IVL, and a real-world clinical and administrational perspective of Coronary IVL within an existing non-surgical facility. A fantastic roundtable discussion and Q+A close the webinar with additional insights regarding Coronary IVL within these important facilities.
The webinar and additional information regarding Coronary IVL and non-surgical facilities can be found at the links below.
Read More
Topics:
Coronary IVL,
Shockwave C2
2022 was another big year for Shockwave and Q4 was no exception! On Twitter, the first Shockwave L6 cases were posted by physicians who participated in its limited release and it was great to see their excitement for our new large-vessel peripheral IVL catheter launching soon in the U.S.! At VIVA ‘22, Dr. Ehrin Armstrong presented the final 1,373 patient cohort data from the Disrupt PAD III Observational Study; this larger patient data set reinforces the predictability of Shockwave IVL and its ability to consistently modify calcium across vessel beds, challenging lesions and complex patients. Additionally, international calcium experts shared their real-world experiences with the safety and efficacy of coronary IVL across different calcium morphologies, including concentric, eccentric and nodular calcium. Check out that and more in the new PulsePoint Newsletter!
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
Coronary Clinical Data,
Peripheral Conferences,
Peripheral Clinical Data,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave S4,
PulsePoint Newsletter,
Calcium Corner,
Shockwave M5 & Shockwave M5+,
Reimbursement,
Treating Different Ca++ Morphologies,
Female vs. Male Outcomes,
Empower CAD
